Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer

被引:14
|
作者
Dang, Yutao [1 ,2 ]
Wang, Ruotian [1 ]
Qian, Kun [1 ]
Lu, Jie [3 ]
Zhang, Haixiang [4 ]
Zhang, Yi [1 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Dept Thorac Surg, Beijing, Peoples R China
[2] Capital Med Univ, Shijingshan Hosp Beijing City, Dept Thorac Surg, Shijingshan Teaching Hosp, Beijing, Peoples R China
[3] Capital Med Univ, Xuanwu Hosp, Dept Radiol, Beijing, Peoples R China
[4] Tianjin Univ, Ctr Appl Math, Tianjin, Peoples R China
来源
关键词
epidermal growth factor receptor mutation; nomogram; non‐ small‐ cell lung cancer; prediction model; radiomics; KRAS GENE-MUTATIONS; EGFR MUTATION; HISTOLOGIC-SUBTYPES; INTRATUMOR HETEROGENEITY; TEXTURE ANALYSIS; ADENOCARCINOMA; FEATURES; ASSOCIATION; SMOKERS; CLASSIFICATION;
D O I
10.1002/acm2.13107
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To determine the prognostic factors of epidermal growth factor receptor (EGFR) mutation status in a group of patients with nonsmall cell lung cancer (NSCLC) by analyzing their clinical and radiological features. Materials and methods Patients with NSCLC who underwent EGFR mutation detection between 2014 and 2017 were included. Clinical features and general imaging features were collected, and radiomic features were extracted from CT data by 3D Slicer software. Prognostic factors of EGFR mutation status were selected by least absolute shrinkage and selection operator (LASSO) logistic regression analysis, and receiver operating characteristic (ROC) curves were drawn for each prediction model of EGFR mutation. Results A total of 118 patients were enrolled in this study. The smoking index (P = 0.028), pleural retraction (P = 0.041), and three radiomic features were significantly associated with EGFR mutation status. The areas under the ROC curve (AUCs) for prediction models of clinical features, general imaging features, and radiomic features were 0.284, 0.703, and 0.815, respectively, and the AUC for the combined prediction model of the three models was 0.894. Finally, a nomogram was established for individualized EGFR mutation prediction. Conclusions The combination of radiomic features with clinical features and general imaging features can enable discrimination of EGFR mutation status better than the use of any group of features alone. Our study may help develop a noninvasive biomarker to identify EGFR mutation status by using a combination of the three group features.
引用
收藏
页码:271 / 280
页数:10
相关论文
共 50 条
  • [31] Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors
    Pathak, A.
    Rajappa, S.
    Gore, A.
    INDIAN JOURNAL OF CANCER, 2017, 54 : S1 - S8
  • [32] Lung cancer patients harbouring epidermal growth factor receptor mutation
    Dias, Catarina
    Araujo, David
    Magalhaes, Adriana
    Queiroga, Henrique
    Espanhol, Venceslau
    Machado, Jose
    Moura, Conceicao
    Marques, Agostinho
    Fernandes, Gabriela
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [33] Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
    Li, Xi
    Li, Wen-Bo
    Luo, Qiang
    Liu, Yuan
    MEDICINE, 2023, 102 (38) : E35081
  • [34] Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer
    Spaans, Johanna N.
    Goss, Glenwood D.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (02) : 102 - 107
  • [35] Impact of age on epidermal growth factor receptor mutation in lung cancer
    Ueno, Tsuyoshi
    Toyooka, Shinichi
    Suda, Kenichi
    Soh, Junichi
    Yatabe, Yasushi
    Miyoshi, Shinichiro
    Matsuo, Keitaro
    Mitsudomi, Tetsuya
    LUNG CANCER, 2012, 78 (03) : 207 - 211
  • [36] Synchronous Primary Lung Cancer and Epidermal Growth Factor Receptor Mutation
    Ma, Edmond S. K.
    Cheng, Paul N. M.
    Wong, Chris L. P.
    Yim, Anthony P. C.
    ANNALS OF THORACIC SURGERY, 2010, 90 (03): : E38 - E39
  • [37] EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION IN NON SMALL CELL LUNG CANCER: VENEZUELAN EXPERIENCE
    Oblitas, George A.
    Garcia, Cristina
    Fuentes, Maria
    Pichelbauer, Ernestina
    Delgado, Jose
    Perez, Maria
    Rodriguez, Juan
    Kubicek, Karen
    Nunez, Patricia
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S117 - S117
  • [38] Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation
    Oikawa, Takefumi
    Ohira, Tatsuo
    Otani, Keishi
    Hagiwara, Masaru
    Konaka, Chimori
    Ikeda, Norihiko
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 329 - 333
  • [39] Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma
    Sharma, Saniya
    Gupta, Nalini
    Singh, Navneet
    Chaturvedi, Rini
    Behera, Digambar
    Rajwanshi, Arvind
    CYTOJOURNAL, 2018, 15
  • [40] k-RAS mutation and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer
    Zhou, Bin
    Tang, Congrong
    Li, Jie
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2017, 13 (04) : 699 - 701